A Phase 2, Open-label, Single-arm Rollover Study to Evaluate Long-term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hematological Disorders.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 02 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 14 Jul 2015 New trial record